Why Did Cassava Sciences Stock Jump 49% Today?

Journal of Neuroscience has informed Cassava Sciences Inc SAVA that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease.
The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company's lead Alzheimer's candidate.
In August, a Citizen Petition was submitted to the FDA alleging, among other things, data manipulation in Western blots in a science article.
Western blotting is a laboratory technique used to separate and measure proteins.
Hence, the Journal requested raw data for the article, including images of original, uncropped Western blots.
After receiving the data and completing its review, the Journal of Neuroscience states: "No evidence of data manipulation was found for Western blot data."
One human error that does not impact data conclusions was identified, and the publisher is expected to print a correction.
Also Read: Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease.
Price Action: SAVA shares closed up 48.96% at $84.40 on Thursday.